Abbott Laboratoriesvs.Quest Diagnostics
ABT vs DGX · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Abbott Laboratories is about 6.8× larger than Quest Diagnostics by market cap; Quest Diagnostics trades at the lower P/E (23.9 vs 31.8); year to date, Quest Diagnostics leads (+33.0% vs −21.4%).
Supply-chain link: Abbott Laboratories supplies Quest Diagnostics.
Side by side
| ABT | DGX | |
|---|---|---|
| Market cap | $172B | $25.4B |
| Price | $99.60 | $230.97 |
| Today | +1.1% | +0.1% |
| Return YTD | −21.4% | +33.0% |
| Return 1Y | −26.6% | +27.6% |
| Since June 26, 2026 | +5.8% | +10.0% |
| P/E | 31.8 | 23.9 |
| P/S | 3.7 | 2.2 |
| P/B | 3.4 | 3.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Abbott LaboratoriesABT
In vitro diagnostics, medical devices that include the Libre glucose sensors, nutrition products and generic medicines: Abbott runs all four.
Full ABT profile →Quest DiagnosticsDGX
A nationwide lab network that does routine testing at volume, with more advanced diagnostics and health data work on top.
Full DGX profile →More ABT & DGX comparisons
Other head-to-heads in the Diagnostics segment.